StockData
REGENXBIO Inc. logo

REGENXBIO Inc. (RGNX) stock

RGNXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 4/30
$7.24−0.08 (-1.09%)

Close on Nov 17, 2026Market cap $477.94MP/E –Yield –

Regenxbio EV/EBITDA

EV/EBITDA is enterprise value divided by EBITDA over the trailing twelve months.

Regenxbio's EV/EBITDA was 3.2× on Jan 31, 2023, against 14.7× a year earlier. Over the last 2 years it ranged from 1.0× to 39.5×, with a median of 14.1×.

EV/EBITDA at the end of each year

PeriodPeriod endValueChange (pts)
2023Jan 31, 20233.2×+0.2
2022Dec 30, 20223.0×−11.6
2019Apr 30, 201914.7×+0.5
2018Dec 31, 201814.1×–

More Regenxbio figures

See a number that looks wrong?